Literature DB >> 12666114

A novel mechanism underlying drug resistance in chronic epilepsy.

Stefan Remy1, Siegrun Gabriel, Bernd W Urban, Dirk Dietrich, Thomas N Lehmann, Christian E Elger, Uwe Heinemann, Heinz Beck.   

Abstract

The development of resistance to pharmacological treatment is common to many human diseases. In chronic epilepsy, many patients develop resistance to anticonvulsant drug treatment during the course of their disease, with the underlying mechanisms remaining unclear. We have studied cellular mechanisms underlying drug resistance in resected hippocampal tissue from patients with temporal lobe epilepsy by comparing two groups of patients, the first displaying a clinical response to the anticonvulsant carbamazepine and a second group with therapy-resistant seizures. Using patch-clamp recordings, we show that the mechanism of action of carbamazepine, use-dependent block of voltage-dependent Na(+) channels, is completely lost in carbamazepine-resistant patients. Likewise, seizure activity elicited in human hippocampal slices is insensitive to carbamazepine. In marked contrast, carbamazepine-induced use-dependent block of Na(+) channels and blocked seizure activity in vitro in patients clinically responsive to this drug. Consistent with these results in human patients, we also show that use-dependent block of Na(+) channels by carbamazepine is absent in chronic experimental epilepsy. Taken together, these data suggest that a loss of Na(+) channel drug sensitivity may constitute a novel mechanism underlying the development of drug-resistant epilepsy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12666114     DOI: 10.1002/ana.10473

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  38 in total

1.  Effects of SCN1A and GABA receptor genetic polymorphisms on carbamazepine tolerability and efficacy in Chinese patients with partial seizures: 2-year longitudinal clinical follow-up.

Authors:  Bo-Ting Zhou; Qiu-Hong Zhou; Ji-Ye Yin; Guo-Liang Li; Jian Qu; Xiao-Jing Xu; Ding Liu; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  CNS Neurosci Ther       Date:  2012-05-17       Impact factor: 5.243

Review 2.  Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function.

Authors:  Bankole A Johnson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

3.  How to explain multidrug resistance in epilepsy?

Authors:  Wolfgang Löscher
Journal:  Epilepsy Curr       Date:  2005 May-Jun       Impact factor: 7.500

Review 4.  Genetics of drug resistance in epilepsy.

Authors:  Sanjay M Sisodiya
Journal:  Curr Neurol Neurosci Rep       Date:  2005-07       Impact factor: 5.081

5.  Drug resistance in epilepsy: is the role of underlying pathology related to multidrug resistance protein?

Authors:  Bassel W Abou-Khalil
Journal:  Epilepsy Curr       Date:  2004 May-Jun       Impact factor: 7.500

6.  Changing channels: mechanisms and responsiveness to antiepileptic drugs in chronic epilepsy.

Authors:  Graeme J Sills
Journal:  Epilepsy Curr       Date:  2004 May-Jun       Impact factor: 7.500

7.  New developments in antiepileptic drug resistance: an integrative view.

Authors:  Dieter Schmidt; Wolfgang Löscher
Journal:  Epilepsy Curr       Date:  2009 Mar-Apr       Impact factor: 7.500

Review 8.  Blood-brain barrier active efflux transporters: ATP-binding cassette gene family.

Authors:  Wolfgang Löscher; Heidrun Potschka
Journal:  NeuroRx       Date:  2005-01

Review 9.  Genetic biomarkers in epilepsy.

Authors:  Yvonne G Weber; Anne T Nies; Matthias Schwab; Holger Lerche
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

Review 10.  Management of the patient with medically refractory epilepsy.

Authors:  Tiziana Granata; Nicola Marchi; Erin Carlton; Chaitali Ghosh; Jorge Gonzalez-Martinez; Andreas V Alexopoulos; Damir Janigro
Journal:  Expert Rev Neurother       Date:  2009-12       Impact factor: 4.618

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.